Mutational topography reflects clinical neuroblastoma heterogeneity
© 2023 The Author(s)..
Neuroblastoma is a pediatric solid tumor characterized by strong clinical heterogeneity. Although clinical risk-defining genomic alterations exist in neuroblastomas, the mutational processes involved in their generation remain largely unclear. By examining the topography and mutational signatures derived from all variant classes, we identified co-occurring mutational footprints, which we termed mutational scenarios. We demonstrate that clinical neuroblastoma heterogeneity is associated with differences in the mutational processes driving these scenarios, linking risk-defining pathognomonic variants to distinct molecular processes. Whereas high-risk MYCN-amplified neuroblastomas were characterized by signs of replication slippage and stress, homologous recombination-associated signatures defined high-risk non-MYCN-amplified patients. Non-high-risk neuroblastomas were marked by footprints of chromosome mis-segregation and TOP1 mutational activity. Furthermore, analysis of subclonal mutations uncovered differential activity of these processes through neuroblastoma evolution. Thus, clinical heterogeneity of neuroblastoma patients can be linked to differences in the mutational processes that are active in their tumors.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:3 |
|---|---|
| Enthalten in: |
Cell genomics - 3(2023), 10 vom: 11. Okt., Seite 100402 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rodriguez-Fos, Elias [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer genomics |
|---|
| Anmerkungen: |
Date Revised 14.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.xgen.2023.100402 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363603492 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363603492 | ||
| 003 | DE-627 | ||
| 005 | 20240214232850.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xgen.2023.100402 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1292.xml |
| 035 | |a (DE-627)NLM363603492 | ||
| 035 | |a (NLM)37868040 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rodriguez-Fos, Elias |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mutational topography reflects clinical neuroblastoma heterogeneity |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Author(s). | ||
| 520 | |a Neuroblastoma is a pediatric solid tumor characterized by strong clinical heterogeneity. Although clinical risk-defining genomic alterations exist in neuroblastomas, the mutational processes involved in their generation remain largely unclear. By examining the topography and mutational signatures derived from all variant classes, we identified co-occurring mutational footprints, which we termed mutational scenarios. We demonstrate that clinical neuroblastoma heterogeneity is associated with differences in the mutational processes driving these scenarios, linking risk-defining pathognomonic variants to distinct molecular processes. Whereas high-risk MYCN-amplified neuroblastomas were characterized by signs of replication slippage and stress, homologous recombination-associated signatures defined high-risk non-MYCN-amplified patients. Non-high-risk neuroblastomas were marked by footprints of chromosome mis-segregation and TOP1 mutational activity. Furthermore, analysis of subclonal mutations uncovered differential activity of these processes through neuroblastoma evolution. Thus, clinical heterogeneity of neuroblastoma patients can be linked to differences in the mutational processes that are active in their tumors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cancer genomics | |
| 650 | 4 | |a clinical heterogeneity | |
| 650 | 4 | |a complex rearrangements | |
| 650 | 4 | |a ecDNA | |
| 650 | 4 | |a mutational processes | |
| 650 | 4 | |a mutational signatures | |
| 650 | 4 | |a neuroblastoma | |
| 650 | 4 | |a structural variation | |
| 650 | 4 | |a tumor evolution | |
| 700 | 1 | |a Planas-Fèlix, Mercè |e verfasserin |4 aut | |
| 700 | 1 | |a Burkert, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Puiggròs, Montserrat |e verfasserin |4 aut | |
| 700 | 1 | |a Toedling, Joern |e verfasserin |4 aut | |
| 700 | 1 | |a Thiessen, Nina |e verfasserin |4 aut | |
| 700 | 1 | |a Blanc, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Szymansky, Annabell |e verfasserin |4 aut | |
| 700 | 1 | |a Hertwig, Falk |e verfasserin |4 aut | |
| 700 | 1 | |a Ishaque, Naveed |e verfasserin |4 aut | |
| 700 | 1 | |a Beule, Dieter |e verfasserin |4 aut | |
| 700 | 1 | |a Torrents, David |e verfasserin |4 aut | |
| 700 | 1 | |a Eggert, Angelika |e verfasserin |4 aut | |
| 700 | 1 | |a Koche, Richard P |e verfasserin |4 aut | |
| 700 | 1 | |a Schwarz, Roland F |e verfasserin |4 aut | |
| 700 | 1 | |a Haase, Kerstin |e verfasserin |4 aut | |
| 700 | 1 | |a Schulte, Johannes H |e verfasserin |4 aut | |
| 700 | 1 | |a Henssen, Anton G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell genomics |d 2021 |g 3(2023), 10 vom: 11. Okt., Seite 100402 |w (DE-627)NLM333578430 |x 2666-979X |7 nnns |
| 773 | 1 | 8 | |g volume:3 |g year:2023 |g number:10 |g day:11 |g month:10 |g pages:100402 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xgen.2023.100402 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 3 |j 2023 |e 10 |b 11 |c 10 |h 100402 | ||